Passage Bio Inc., a clinical stage genetic medicines company, reported its financial results for the first quarter ending March 31, 2025. The company recorded a net loss of $15.4 million for the quarter, or $0.25 per basic and diluted share, compared to a net loss of $16.7 million, or $0.30 per basic and diluted share, in the same period the previous year. Research and Development (R&D) expenses decreased to $7.7 million from $11.5 million year-over-year, while General and Administrative (G&A) expenses slightly declined to $6.1 million from $6.5 million in the prior year. The company reported a cash position, including cash equivalents and marketable securities, of $63.4 million as of March 31, 2025, down from $104.5 million a year earlier. Passage Bio forecasts that the current cash reserves will sustain operations into the first quarter of 2027. In terms of business operations, Passage Bio made significant progress in its ongoing global Phase 1/2 upliFT-D trial of PBFT02, focusing on the enrolment of FTD-_GRN_ and FTD-_C9orf72_ patients. A significant milestone was achieved as the first FTD-GRN patient was treated with Dose 2 PBFT02, and a second patient was enrolled with several others under evaluation for trial eligibility. The company anticipates reporting 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in the second half of 2025 and plans to seek regulatory feedback on the registrational trial design in the first half of 2026. Additionally, the dosing of FTD-_C9orf72_ patients is expected to commence in the first half of 2025.